From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community

被引:77
作者
Frueh, FW [1 ]
Gurwitz, D
机构
[1] Stepoutside Consulting LLC, Gaithersburg, MD 20878 USA
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
adverse drug reactions; bioethics; CYP450; enzymes; FDA guidelines; medical education; personalized medicine; pharmacodynamics; pharmacogenetics; pharmacogenomics; pharmacokinetics; population studies;
D O I
10.1517/14622416.5.5.571
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The field of pharmacogenetics will soon celebrate its 50th anniversary. Although science has delivered an impressive amount of information in these 50 years, pharmacogenetics has suffered from lack of integration into clinical practice. There are several reasons for this, including the unmet need for education at medical schools and the lack of awareness about the impact of genetic medicine on healthcare in the community. Recently, the FDA announced that it considers pharmacogenomics one of three major opportunities on the critical path to new medical products. This notion by the FDA is filling the regulatory void that existed between drug developers and drug users. However, in order to bring pharmacogenetic testing to the prescription pad successfully, healthcare professionals and policy makers, as well as patients, need to have the necessary background knowledge for making educated treatment decisions. To effectively move pharmacogenetics into everyday medicine, it is therefore imperative for scientists and teachers in the field to take on the challenge of disseminating pharmacogenetic insights to a broader audience.
引用
收藏
页码:571 / 579
页数:9
相关论文
共 75 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] Anderson Jeffrey L., 2003, Journal of Cardiovascular Pharmacology and Therapeutics, V8, P71, DOI 10.1177/107424840300800i110
  • [3] [Anonymous], 1923, Inborn Errors of Metabolism
  • [4] Arnardottir O M, 1999, Eur J Health Law, V6, P307, DOI 10.1163/15718099920522910
  • [5] UK Blobank: a project in search of a protocol?
    Barbour, V
    [J]. LANCET, 2003, 361 (9370) : 1734 - 1738
  • [6] Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations
    Baudin, B
    [J]. PHARMACOGENOMICS, 2002, 3 (01) : 65 - 73
  • [7] Molecular genetics of CYP2D6:: Clinical relevance with focus on psychotropic drugs
    Bertilsson, L
    Dahl, ML
    Dalén, P
    Al-Shurbaji, A
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (02) : 111 - 122
  • [8] BESTEHEN BEZIEHUNGEN ZWISCHEN DER HOHE DER ISONICOTINSAUREHYDRAZID-AUSSCHEIDUNG UND DEM THERAPEUTISCHEN BEHANDLUNGSERGEBNIS
    BONICKE, R
    ORLOWSKI, EH
    [J]. KLINISCHE WOCHENSCHRIFT, 1955, 33 (33-4): : 803 - 806
  • [9] Pharmacogenetics: Ethical issues and policy options
    Buchanan, A
    Califano, A
    Kahn, J
    McPherson, E
    Robertson, J
    Brody, B
    [J]. KENNEDY INSTITUTE OF ETHICS JOURNAL, 2002, 12 (01) : 1 - 15
  • [10] Pharmacogenomics of hypertension
    Cadman, PE
    O'Connor, DT
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2003, 12 (01) : 61 - 70